Science brief
The New Frontiers of Israeli Biotech
Weizmann Institute breakthroughs target cancer and food security while a new NIS 70M consortium anchors generative AI in medicine.
Science
Weizmann scientists have proved sildenafil restricts cancer metastasis — exposing a cheap, repurposed drug pathway that could fast-track human trials and bypass years of standard safety development.
BackgroundMetastatic cancer cells heavily rely on cholesterol to structurally alter their membranes, allowing them to break away and invade distant organs. Sildenafil blocks the PDE5 enzyme, increasing a signaling molecule that binds to and disables a key cholesterol transporter.
- The research team analyzed 5 million Israeli digital health records, finding significantly improved survival rates in cancer patients who happened to take sildenafil, validating the lab's findings in real-world cohorts.
- Combining sildenafil with common statin drugs produced an additive therapeutic benefit in testing, opening a potential path for highly affordable, repurposed combination therapies that can be deployed quickly.
- Clinical trials will need to confirm the dosage requirements for human patients to achieve similar anti-metastatic effects, risking potential delays if systemic cardiovascular issues arise at therapeutic levels.
Science
Weizmann scientists have engineered bacteria to produce protein from solar energy and CO2 — a lab milestone that could make food production independent of land and climate constraints.
BackgroundTraditional agriculture requires vast tracts of arable land and fresh water to produce protein-rich crops like soybeans. The research aims to decouple food production from soil constraints by utilizing highly efficient bacterial bioconversion systems in closed environments.
- The engineered bacteria utilize solar-powered systems to capture and convert carbon dioxide into edible protein structures, offering a closed-loop food source that is entirely independent of local weather conditions.
- Calculations indicate that a single dunam of solar-powered bioreactors can yield 10 times more protein than the same area planted with soybeans, drastically reducing the physical footprint of agriculture.
- Scaling the process requires substantial infrastructure investment, as industrial bioreactors must maintain strict temperature and light parameters to prevent contamination and keep the bacteria growing rapidly.
Science
Israel is deploying NIS 70M to build a national AI-biology consortium — a collaborative infrastructure project designed to cement the country's lead in AI-driven precision drug discovery.
BackgroundBiological data is highly fragmented and complex, making it difficult for standard machine learning models to analyze effectively. The consortium brings together domestic research institutes and corporate giants to build a shared, standardized technological database.
- NVIDIA, Teva, and Sheba Medical Center are anchoring the project alongside top academic researchers, bringing together computational power, pharmaceutical expertise, and deep clinical data sets under one umbrella.
- The project will develop standardized 'Bio Tokens' to represent complex biological molecules, allowing generative AI models to accurately predict how individual patient cells will respond to specific treatments.
- Participating startups will gain free access to pre-competitive infrastructure, lowering the massive computational cost of developing precision therapies and helping local biotechnology firms compete with foreign giants.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.